Search Results - Masamichi Mori
- Showing 1 - 4 results of 4
-
1
Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia by Masamichi Mori, Naoki Kaneko, Yoko Ueno, Masaki Yamada, Ruriko Tanaka, Rika Saito, Itsuro Shimada, Kenichi Mori, Sadao Kuromitsu
Published 2017Artigo -
2
Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells by Tatsuya Kawase, Taisuke Nakazawa, Tomohiro Eguchi, Hirofumi Tsuzuki, Yoko Ueno, Y. Amano, Tomoyuki Suzuki, Masamichi Mori, Taku Yoshida
Published 2019Artigo -
3
Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade by Shinsuke Nakao, Yukinori Arai, Mamoru Tasaki, M. Yamashita, Ryuji Murakami, Tatsuya Kawase, Nobuaki Amino, Motomu Nakatake, Hajime Kurosaki, Masamichi Mori, Masahiro Takeuchi, Takafumi Nakamura
Published 2020Artigo -
4
The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model Mice by Masamichi Mori, Yoko Ueno, Satoshi Konagai, Hiroshi Fushiki, Itsuro Shimada, Yutaka Kondoh, Rika Saito, Kenichi Mori, Nobuaki Shindou, Takatoshi Soga, Hideki Sakagami, Takashi Furutani, Hitoshi Doihara, Masafumi Kudoh, Sadao Kuromitsu
Published 2014Artigo
Search Tools:
Related Subjects
Cancer research
Biochemistry
Biology
Gene
Cancer
Chemistry
Fms-Like Tyrosine Kinase 3
Immunology
Internal medicine
Medicine
Mutation
Myeloid leukemia
Signal transduction
Tyrosine kinase
Tyrosine-kinase inhibitor
ALK inhibitor
Anaplastic lymphoma kinase
Blockade
Bone marrow
Cell biology
Chemotherapy
Cisplatin
Crizotinib
Genetics
Immune checkpoint
Immune system
Immunotherapy
Leukemia
Lung cancer
Malignant pleural effusion